| Health / Medical Topics |
Caricotamide/Tretazicar
A combination therapy consisting of the prodrug tretazicar and the enzyme co-substrate caricotamide with potential antineoplastic activity. In the presence of separately and simultaneously administered caricotamide, tretazicar is converted to the short-lived cytotoxic DNA cross-linking agent dinitrobenzamide by NAD(P)H quinine oxidoreductase 2 (NQO2), resulting in the inhibition of DNA replication and the induction of apoptosis. NQO2 has been found to be elevated in certain cancers such as hepatocellular carcinoma (HCC). (NCI Thesaurus)
YOU MAY ALSO LIKE
A synthetic co-substrate that activates the human endogenous enzyme NRH:quinone oxidoreductase 2 (NQO2) with potential chemoadjuvant activity. When caricotamide is administered simultaneously…
Denotes a person having origins in one of the indigenous people of the Caribbean.
A group of islands in the Caribbean Sea. These islands curve southward from the bottom tip of Florida to the Northwest of…
An orally active, synthetic structural analogue of N-acetylglutamate (NAG) and carbamoyl phosphate synthetase 1 (CPS 1) activator, with ammonia lowering activity. NAG,…
A drug used to treat multiple myeloma that has not gotten better with other anticancer drugs. It is also being studied in…
Caregivers provide help to another person in need. The person receiving care may be an adult - often a parent or a…
